Literature DB >> 19557315

Intravenous immunoglobulin in lupus panniculitis.

João Espírito Santo1, M F Gomes, M J Gomes, L Peixoto, S C Pereira, A Acabado, J Freitas, G Vinhas de Sousa.   

Abstract

Systemic lupus erythematosus (SLE) is a disease of unknown cause that may involve one or many organ or systems. Skin involvement is a major feature in this disease, and a wide variety of skin conditions may be present. Lupus erythematosus panniculitis (LEP) constitutes a rare form of cutaneous lupus characterized by recurrent nodular or plaque lesions that can vary from a benign and mild course to a more disfiguring disease. Initial therapy includes corticosteroids, antimalarials, and azathioprine and, in refractory cases, two antimalarials in association, mycophenolate mofetil, or other immunomodulators. Intravenous immuglobulin (IVIG) is used in many autoimmune disorders, like in SLE, although clinical trials have not yet taken place. In this report, we review skin manifestations of SLE and their treatment, IVIG, and finally a case of LEP successfully treated with IVIG when other therapy modalities failed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19557315     DOI: 10.1007/s12016-009-8162-x

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  77 in total

1.  Histiocytic cytophagic panniculitis: molecular evidence for a clonal T-cell disorder.

Authors:  P Hytiroglou; R G Phelps; D J Wattenberg; J A Strauchen
Journal:  J Am Acad Dermatol       Date:  1992-08       Impact factor: 11.527

Review 2.  Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network.

Authors:  G Dietrich; S V Kaveri; M D Kazatchkine
Journal:  Clin Immunol Immunopathol       Date:  1992-01

3.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

Review 4.  Treatment of systemic lupus erythematosus with mycophenolate mofetil.

Authors:  D Adu; J Cross; D R Jayne
Journal:  Lupus       Date:  2001       Impact factor: 2.911

5.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

6.  Is corneal deposition of antimalarial any indication of retinal toxicity?

Authors:  M Easterbrook
Journal:  Can J Ophthalmol       Date:  1990-08       Impact factor: 1.882

7.  Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases.

Authors:  Y Sherer; Y Levy; P Langevitz; L Rauova; F Fabrizzi; Y Shoenfeld
Journal:  Pharmacology       Date:  2001       Impact factor: 2.547

8.  High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events.

Authors:  M C Dalakas
Journal:  Neurology       Date:  1994-02       Impact factor: 9.910

9.  Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets.

Authors:  M C Hochberg; R E Boyd; J M Ahearn; F C Arnett; W B Bias; T T Provost; M B Stevens
Journal:  Medicine (Baltimore)       Date:  1985-09       Impact factor: 1.889

10.  Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin.

Authors:  R Voltz; F V Rosen; T Yousry; J Beck; R Hohlfeld
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

View more
  11 in total

1.  Update on management of connective tissue panniculitides.

Authors:  Inbal Braunstein; Victoria P Werth
Journal:  Dermatol Ther       Date:  2012 Mar-Apr       Impact factor: 2.851

2.  The future of autoimmunity.

Authors:  Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 3.  Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Wien Med Wochenschr       Date:  2017-09-01

4.  Mechanisms and pathophysiology of autoimmune disease.

Authors:  Wesley H Brooks
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

5.  Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

Authors:  R R Winkelmann; Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-01

Review 6.  Indications for IVIG in rheumatic diseases.

Authors:  Ben Mulhearn; Ian N Bruce
Journal:  Rheumatology (Oxford)       Date:  2014-11-17       Impact factor: 7.580

7.  Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study.

Authors:  Christa Ky; Brian Swasdibutra; Shaadi Khademi; Sheetal Desai; Vivian Laquer; Sergei A Grando
Journal:  Dermatol Reports       Date:  2015-03-16

8.  Lupus profundus limited to a site of trauma: Case report and review of the literature.

Authors:  María Adriana Castrillón; Dédée F Murrell
Journal:  Int J Womens Dermatol       Date:  2017-05-05

9.  Lupus erythematosus panniculitis resistant to standard treatment, complicated with macrophage activation syndrome.

Authors:  Katarzyna Juczynska; Anna Wozniacka; Elzbieta Waszczykowska; Agnieszka Zebrowska
Journal:  Postepy Dermatol Alergol       Date:  2017-05-29       Impact factor: 1.837

Review 10.  Cutaneous lupus erythematosus: A review of the literature.

Authors:  Stephanie Clare Blake; Benjamin Silas Daniel
Journal:  Int J Womens Dermatol       Date:  2019-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.